Free Trial
NASDAQ:EDIT

Editas Medicine Q4 2024 Earnings Report

Editas Medicine logo
$1.28 +0.02 (+1.18%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$1.25 -0.03 (-2.72%)
As of 04/17/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Editas Medicine EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.39
Beat/Miss
Missed by -$0.16
One Year Ago EPS
-$0.23

Editas Medicine Revenue Results

Actual Revenue
$30.60 million
Expected Revenue
$37.17 million
Beat/Miss
Missed by -$6.57 million
YoY Revenue Growth
N/A

Editas Medicine Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 5, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Editas Medicine's Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Editas Medicine Earnings Headlines

Leerink Partnrs Comments on Editas Medicine Q3 Earnings
Leerink Partnrs Estimates Editas Medicine Q1 Earnings
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
City Therapeutics Expands Executive Team and Board of Directors
See More Editas Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Editas Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Editas Medicine and other key companies, straight to your email.

About Editas Medicine

Editas Medicine (NASDAQ:EDIT), a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

View Editas Medicine Profile

More Earnings Resources from MarketBeat